A recent study published in 2026 reveals that first-line treatments for erectile dysfunction (ED), particularly phosphodiesterase 5 inhibitors (PDE5i) such as Viagra and Cialis, remain significantly under-prescribed among patients with prostate cancer, despite their proven clinical efficacy. Researchers have uncovered that over 80% of men undergoing treatment for prostate cancer experience poor or very poor erections. This condition is often exacerbated by various treatments, including radiotherapy, hormone therapy, and prostatectomy.
Guidelines from the National Institute for Health and Care Excellence (NICE) endorse PDE5i as the recommended drug treatment for ED in prostate cancer survivors. These medications work by blocking an enzyme that constricts blood flow, thereby facilitating better circulation to crucial areas, which helps not only with erectile function but also offers potential benefits for heart, brain, and lung health. Prostate Cancer UK advocates for healthcare providers to prescribe PDE5i as early as possible during the treatment process, emphasizing the importance of addressing sexual health in male cancer survivors.
The study further highlights the positive relationship between the use of PDE5i and favorable clinical outcomes, especially in patients dealing with common co-morbidities associated with prostate cancer, such as cardiovascular issues and diabetes. Evidence suggests that PDE5i can also aid in alleviating urological conditions like lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). However, it is essential to note that certain patients should avoid these medications, including those with unstable angina, recent strokes, or renal impairments.
Despite the clear advantages of PDE5i, their usage is alarmingly low within the context of NICE recommendations. A 2025 survey indicated that only 13% of prostate cancer survivors were current users of these treatments, a figure that pales in comparison to 9% in the general male population. Historically, high costs limited access to these medications through the NHS, but the expiration of patents over the past decade has made them significantly more affordable. As a result, patients are now encouraged to discuss PDE5i options with their general practitioners.
The findings compel a reevaluation of prescribing practices among clinicians, aiming to enhance the quality of life for male patients navigating the challenges of prostate cancer treatment. By prioritizing erectile dysfunction management, healthcare providers can play a crucial role in supporting the emotional and physical well-being of their patients.
With the growing body of evidence underscoring the benefits of PDE5i for prostate cancer survivors, it is clear that addressing erectile dysfunction should be a key component of comprehensive cancer care. In light of these findings, both healthcare professionals and patients stand to gain from increased awareness and communication about treatment options.
In summary, the path forward involves both the acknowledgment of the widespread impact of ED among prostate cancer patients and the urgent need to leverage available treatments effectively.
References:
- Naranjo A et al. Evidence for the Additional Health Benefits Associated with Phosphodiesterase 5 Inhibitors when Used for Treating Erectile Dysfunction, with a Focus on Prostate Cancer Patients and Other Associated Conditions. World J Mens Health. 2026; DOI:10.5534/wjmh.250313.
- Downing A et al. Quality of life in men living with advanced and localized prostate cancer in the UK: a population-based study. Lancet Oncol. 2019; 20:436-447.
- National Institute for Health and Care Excellence (NICE). Erectile dysfunction: phosphodiesterase-5 (PDE-5) inhibitors. Available at: https://news.google.com/rss/articles/CBMiqAFBVV95cUxQVG1kV0N5RjFta1BaSEJQa2RvNHBTTEU1M3ZTMWF2bFQ4aTAwajU2UnhhQ2t2YVM1bk94Y0JvXzBNTE1YQUFWcklUS2VubkQtVGthYVBvQnlHQ3FpWHkwRXdCZW5fdkF1U2hhVEVoY0hDZnMxTzBBOWpxb1V4cmRFbDFBYS1ORmVnVkxqaTlSUG1mOU1ZRVd0WVktTGJ3ZkprZXU5eWppMGs?oc=5. Last accessed: 3 March 2026.
- Prostate Cancer UK. More men with prostate cancer could benefit from erection pills, new research shows. Available at: https://news.google.com/rss/articles/CBMiqAFBVV95cUxQVG1kV0N5RjFta1BaSEJQa2RvNHBTTEU1M3ZTMWF2bFQ4aTAwajU2UnhhQ2t2YVM1bk94Y0JvXzBNTE1YQUFWcklUS2VubkQtVGthYVBvQnlHQ3FpWHkwRXdCZW5fdkF1U2hhVEVoY0hDZnMxTzBBOWpxb1V4cmRFbDFBYS1ORmVnVkxqaTlSUG1mOU1ZRVd0WVktTGJ3ZkprZXU5eWppMGs?oc=5. Last accessed: 3 March 2026.
- Dahl AA et al. A controlled study of use and effectiveness of phosphodiesterase-5 inhibitors in long-term survivors after curative radiotherapy for prostate cancer (PCa). Radiother Oncol. 2025; DOI: 10.1016/j.radonc.2024.110704.
Original Source: https://www.emjreviews.com/urology/news/erection-pills-under-prescribed-in-patients-with-prostate-cancer/
Category :
Tags:
Publish Date: 2026-03-03 16:34:00
